Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment System

Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver combined femto phaco technology. If capproved, the combined femtosecond laser and phacoemulsification system would be the first system to combine these technologies.

The current ALLY System provides surgeons have the option of performing FLACS procedures in a sterile environment, moving seamlessly from laser to phaco, saving between 8 and 10 minutes per procedure with ALLY, according to Lensar. The combined system would allow surgeons to also save space in the operating room and optimize cataract surgery all on one system.

“We are extremely proud to bring best-in-class phaco technology, developed by Oertli, as an option to our customers. This combined system will be the first ever on the market, demonstrating our commitment to change the paradigm in cataract surgery," Nick Curtis, CEO of Lensar, said in a company news release. "ALLY will offer even more ways for surgeons to optimize their workflow and improve the patient experience."

LENSAR will be exhibiting at AAO 2023, San Francisco, booth #1933, November 4-6, 2023.